Drs. Koen Van Besien, Jingmei Hsu, and Marshall Glesby have led a clinical trial involving a patient living with HIV who has now been free of the virus for 14 months.
This one-time grant will support Dr. Morales’s project focused on understanding the role of an oncoprotein, Wilms' Tumor 1, in HIV-Associated Kaposi Sarcoma.
As highlighted in the WDOM’s 2021 Annual Report, Dr. S. Louis “Lou” Bridges, Jr., Chief, Division of Rheumatology, WDOM, remains focused on optimizing new approaches in clinical research and mentoring.
The study employed a sophisticated computer modeling platform built in response to the COVID-19 pandemic.
Dr. Cristofanilli's many scientific advances in the field of breast cancer include novel biomarkers (endocrine), findings on circulating tumor cells, and drug development with a focus on endocrine therapy.
The award will support Dr. Landau’s development of novel technology to study clonal mosaicism in normal tissues. This research will open a critical window into the earliest stages of cancer formation.
The research suggests that countering the activity of inflammatory ILC3s could lead to a therapeutic approach for multiple sclerosis and other brain disorders.
These findings have opened a window into the development of inflammatory bowel disease (IBD), as well as insights into a rare syndrome in which the SATB2 gene is disrupted.
Lectures were provided by WDOM faculty and keynote speaker, Dr. Drew Weissman, who played a major role in critical discoveries that allowed for the mRNA platform to be used in developing vaccines against SARS-CoV.
The researchers found that SARS-CoV-2 triggers an inflammatory antiviral response in the adipose tissue (body fat) and causes its dysfunction.
